The FDA has granted approval for Johnson & Johnson's Imaavy, marking a significant treatment option for patients suffering from warm autoimmune hemolytic anemia. This approval expands therapeutic choices for a rare blood disorder previously lacking targeted therapies.

An article examines whether Johnson & Johnson's proposed $5.5 billion settlement for talc-related lawsuits signals a resolution to its legal risks or if further challenges remain for investors.

Three scientists have successfully defended against a defamation lawsuit filed by Johnson & Johnson concerning their research on talc and its potential link to cancer. This victory allows their research to continue without legal impediment from the company.

Major pharmaceutical companies like Bristol Myers and Johnson & Johnson are reportedly observing Seaport following its Initial Public Offering (IPO).

Eli Lilly and Johnson & Johnson shares saw a bounce after new data was released, while software stocks gave up their gains from the previous week.

This article evaluates Johnson & Johnson and Medtronic's stock positions following their recent earnings reports, assessing which healthcare company is better positioned in the market.

Johnson & Johnson's Ottava has received FDA approval, raising questions about its potential to challenge Intuitive Surgical in the medical device market.

Financial analyst Jim Cramer provided insights into Johnson & Johnson's stock performance following the company's achievement of a significant milestone in surgical robotics.

The Federal Reserve's recent decision on interest rates is being viewed as a test of its credibility, alongside news of Johnson & Johnson's new strategic investment.

A recent settlement involving Johnson & Johnson has reignited discussions and questions about whether talcum powder truly increases the risk of ovarian cancer. The legal action brings the long-standing debate back into public focus.

Johnson & Johnson has secured a $2.58 billion option to acquire Sail's in vivo CAR-T therapies. This strategic move aims to bolster Johnson & Johnson's presence in the rapidly evolving field of cell-based cancer treatments.

Johnson & Johnson has offered a $5.5 billion settlement to resolve tens of thousands of lawsuits alleging that its talc-based products, including baby powder, caused cancer.

Johnson & Johnson has proposed a $5.5 billion settlement to resolve thousands of lawsuits alleging its talc-based baby powder caused cancer, aiming to end a protracted legal battle.

An investment analysis evaluates whether AbbVie or Johnson & Johnson is the better 'Dividend King' stock to buy, focusing on their appeal for dividend-focused investors.

Pharmaceutical companies Johnson & Johnson and Gilead Sciences were among those receiving drug recommendations from the European Union this week. These recommendations are part of the EU's regulatory process for new and existing medicines.

Johnson & Johnson has announced its entry into the US robotic surgery market after securing FDA approval for its Ottava robotic surgical system, which is authorized for several general surgery procedures.

Johnson & Johnson has received FDA approval for its Ottava soft tissue surgical robot. This development has led to a decline in the stock of competitors like Intuitive Surgical and Medtronic.

An analysis questions whether it is still a good time to invest in Johnson & Johnson stock following its recent strong earnings report.

An article investigates the reasons behind the market's negative reaction to Johnson & Johnson (JNJ) stock, exploring factors contributing to its underperformance.

Midday market news indicates that Johnson & Johnson has beaten its earnings estimates, while the Producer Price Index (PPI) has shown a drop.

Johnson & Johnson announced that it has beaten its second-quarter earnings estimates and subsequently raised its full-year 2026 guidance.

Johnson & Johnson's stock experienced a dip despite an upbeat outlook, while AstraZeneca and Spero Therapeutics announced new deals in China.

An analysis compares Johnson & Johnson (JNJ) and Coca-Cola (KO) to determine which dividend stock presents a better investment opportunity.

Jim Cramer provided his opinions on various stocks, recommending some like Preformed Line Products, IREN, Nebius, CoreWeave, Goldman Sachs, Solstice, and Deere & Company, while expressing caution or negative views on others such as Nextpower, Chewy, and Costco.

Johnson & Johnson (JNJ) was identified by Jim Cramer as one of his top-performing stocks projected for 2026, highlighting its long-term investment potential.

Members of Congress are reportedly investing heavily in Johnson & Johnson and UnitedHealth, drawing attention from retail investors.

Johnson & Johnson (JNJ) is highlighted as a top dividend aristocrat stock, with its strategic focus on cancer and neuroscience driving its investment appeal.

Healthcare stocks, including AbbVie, Eli Lilly, and Johnson & Johnson, are reaching all-time highs as investors shift their focus from the technology sector to biopharmaceuticals.

An analysis compares Bristol Myers Squibb and Johnson & Johnson to determine which healthcare stock presents a better investment opportunity for 2026.

An earnings preview for Johnson & Johnson has been released, outlining what analysts and investors can expect from the company's upcoming financial report.

Pharmaceutical company Johnson & Johnson secured a €58,000 reduction against a High Court award of almost €1 million to a former Limerick senior hurler.

An article analyzes the potential annual dividend income for an investor holding 500 shares each of pharmaceutical giants Pfizer and Johnson & Johnson.

Johnson & Johnson has announced plans to invest more than $1 billion in a new contact lens manufacturing facility in Florida.

Jim Cramer provided an explanation for the recent gains observed in Johnson & Johnson's shares.

Johnson & Johnson (JNJ) stock remains flat even after the company reportedly raised its performance expectations, prompting analysis into the market's reaction.

Johnson & Johnson (JNJ) stock experienced a jump, driven by overall market optimism.

Johnson & Johnson has released data to support the expansion of Imaavy's label for a rare autoimmune disease linked to anemia, aiming to broaden its therapeutic indications.

A jury in Los Angeles has awarded $32 million to a plaintiff in a talc-related cancer case against Johnson & Johnson.

Johnson & Johnson has been cleared in a talc-related cancer lawsuit in California, marking a legal victory for the company.

Johnson & Johnson's experimental drug for lupus has successfully met its primary endpoint in a Phase 2 clinical study, marking a positive step in its development.

A late-stage study has shown that Johnson & Johnson's prostate cancer drug significantly reduces the risk of cancer spread and death in patients.

An article examines Johnson & Johnson's successful strategy in securing cancer biotech deals at favorable prices. It questions whether the pharmaceutical giant can maintain its innovative edge in the competitive biotechnology landscape.

This article analyzes the distinct growth strategies and prospects of pharmaceutical giants Johnson & Johnson and AbbVie.

Johnson & Johnson has announced that its drug nipocalimab has received approval for use in China.

An article explores whether Johnson & Johnson (JNJ) is one of the best "Dogs of the Dow" stocks to consider buying for the remainder of 2026.

Johnson & Johnson believes its new psoriasis pill, Icotyde, has the potential to become one of its most significant drugs. Investors are closely watching such new medications to boost the company's revenue growth.

Johnson & Johnson has received an upgrade from Leerink, citing positive growth prospects for the company. The upgrade reflects confidence in J&J's future performance and market position.

Wall Street analysts issued research calls on Wednesday for several companies including Advanced Micro Devices, Akamai Technologies, HEICO, Johnson & Johnson, MasTec, MercadoLibre, Sandisk, and Snap.

Johnson & Johnson is promoting new data supporting Caplyta as an effective add-on therapy for depression.

Ramez Mohsen-Fawzi, managing director of Johnson & Johnson Innovative Medicine for Europe, emphasizes that investing in health is crucial for economic success.

A drug developed from ketamine has reportedly become a $1.7 billion blockbuster for Johnson & Johnson, highlighting its significant market success.

Ramez Mohsen Fawzi, Managing Director for Johnson & Johnson Innovative Medicine in Europe, states that investing in health is essential for economic success. He emphasizes that a functional economy cannot be maintained if its participants are struggling with illnesses.

Johnson & Johnson anticipates that artificial intelligence will significantly reduce the time required to generate drug development leads by half. This projection highlights the growing role of AI in accelerating pharmaceutical research and innovation.

Johnson & Johnson is reportedly planning to launch four of its prescription drugs on the TrumpRx platform, according to a CBS News report. This move signifies a new distribution channel for the pharma

An analysis suggests Johnson & Johnson (JNJ) is a strong counter-cyclical stock, making it a potentially resilient investment during economic downturns. The article explores reasons why it might be a good buy in the current market.

Analysts are evaluating Johnson & Johnson as a potential buy, citing its consistent sales growth and solid financial guidance provided for 2026.

Johnson & Johnson (JNJ) has been identified as one of 12 high-dividend stocks selected by billionaire investor Ray Dalio.

A U.S. judge has rejected Bayer's attempt to block claims related to Johnson & Johnson's prostate cancer drug. This ruling allows the legal proceedings concerning the drug to continue.

Johnson & Johnson has reported its first-quarter earnings, setting a positive tone for the season with significant growth in its oncology division.

Following its Q1 earnings results, financial analysts suggest that Johnson & Johnson's stock could easily see a 20% gain. The positive outlook is based on the company's recent financial performance and market projections.

Jim Cramer advises investors to consider buying Johnson & Johnson stock if it experiences a significant dip in value.

Johnson & Johnson's cardiovascular unit has once again demonstrated strong performance in the first quarter of the year.

Johnson & Johnson reported sales that surpassed expectations, primarily attributed to strong growth in its cancer medicine segment.

Several prominent companies, including Johnson & Johnson, Netflix, TSMC, Goldman Sachs, Citigroup, JPMorgan Chase, Bank of America, and PepsiCo, are scheduled to release their earnings reports in the coming week. Investors will be closely watching these announcements for insights into corporate performance and economic trends.

Financial analysts highlight four notable equities—META, DKS, JNJ, and HIMS—for potential market movements, citing sector trends and upcoming catalysts.

The U.S. Food and Drug Administration (FDA) has granted approval to Johnson & Johnson's drug Imaavy. This new treatment is approved for warm autoimmune hemolytic anemia, a rare blood disorder.

Multiple analyses compare investment opportunities among leading healthcare companies such as Medtronic, Thermo Fisher, Abbott, Johnson & Johnson, and Danaher. These comparisons focus on aspects like turnaround potential, diversification, growth stories, and recovery prospects.

Johnson & Johnson has announced the appointment of a new vice president to oversee its litigation matters.

Johnson & Johnson's stock performance is reportedly influenced by an internal calendar rather than typical market cycles, suggesting a unique operational rhythm for the pharmaceutical giant.

Johnson & Johnson has reached a $5.5 billion settlement regarding talc-related lawsuits, raising questions about whether this marks a turning point or offers only temporary relief for the company.

This article analyzes whether Johnson & Johnson or Abbott Laboratories offers a more compelling growth story in the healthcare sector following their recent earnings reports.

Johnson & Johnson is reportedly offering $5.5 billion to bring an end to long-running lawsuits alleging that its talc products caused cancer.

This week's notable healthcare headlines highlight developments concerning pharmaceutical companies Curium, Bristol-Myers Squibb, and Johnson & Johnson.

An analysis compares Abbott Laboratories and Johnson & Johnson to determine which healthcare stock presents a better investment opportunity for the year 2026.

Johnson & Johnson has received FDA priority review for its Rybrevant Faspro treatment, specifically for use in head and neck cancer, potentially accelerating its availability.

An analysis highlights a particular stock that is significantly outperforming pharmaceutical giants Eli Lilly, Johnson & Johnson, and AbbVie. The article likely delves into the reasons for its strong performance.

Johnson & Johnson has raised its financial outlook following its latest earnings report, prompting questions about its position as a leading healthcare stock.

Notable insider trading activities have been reported, involving companies such as Johnson & Johnson and TSMC.

Johnson & Johnson has introduced a rival to Intuitive Surgical's da Vinci robotic surgery system, but market analysts suggest it may not significantly impact J&J's stock given Intuitive Surgical's strong performance.

Shares of Intuitive Surgical (ISRG) experienced a decline today, attributed to recent developments and news concerning Johnson & Johnson.

An analysis compares the differing trajectories of healthcare giants Johnson & Johnson and Abbott Laboratories, highlighting their current market positions and future outlooks.

This week's notable healthcare headlines highlight developments concerning major industry players such as UnitedHealth, Johnson & Johnson, and Intuitive Surgical.

Johnson & Johnson has raised its full-year 2026 outlook after reporting positive results for the second quarter.

An analysis compares Walmart and Johnson & Johnson as defensive stock plays, highlighting their diverging strategies. The article aims to identify which of these two companies presents a stronger investment opportunity.

Johnson & Johnson's upcoming second-quarter earnings report is expected to draw attention to the healthcare giant's new product launches and its development pipeline, showcasing its potential beyond being a rotation winner.

An analysis suggests a strong case for investing in Johnson & Johnson (JNJ) shares before July 15, highlighting potential market opportunities.

Johnson & Johnson has been granted FDA approval for its integrated catheter ablation solution, marking a significant development in medical technology.

An analysis pits "Dividend King" Johnson & Johnson against "Growth Giant" Eli Lilly, evaluating their respective investment merits.

Johnson & Johnson (JNJ) stock is experiencing a standoff, with company management anticipating a breakout while the broader market holds a more cautious, stagnant view.

An analysis compares Bristol Myers Squibb and Johnson & Johnson to determine which healthcare stock is a better investment buy for 2026.

Johnson & Johnson stock experienced a notable increase on Friday, with analysts examining the factors behind its sudden pop.

Johnson & Johnson (JNJ) is highlighted as one of the best stocks for beginner investors to consider buying now.

The CEO of Johnson & Johnson has conveyed a definitive message regarding the rapidly expanding market for obesity drugs, signaling the company's stance or strategy within this burgeoning pharmaceutical sector.

Former Limerick hurler Mark Keane's almost €1 million damages award has been reduced by €58,000 on appeal against Johnson & Johnson. The appeal resulted in a significant reduction of the initial compensation.

Momentum in Johnson & Johnson's pharmaceutical division is reportedly fueling the company's path towards achieving double-digit upside in its financial performance.

The CEO of Johnson & Johnson stated that a cure for certain cancers is a "realistic" goal within the next decade. He cited significant progress in treatments for multiple myeloma and immunotherapy as reasons for his optimism.

Johnson & Johnson's multiple myeloma drug, Talvey, has demonstrated a reduction in mortality risk by up to 53% in a late-stage clinical trial, according to new findings.

Johnson & Johnson has reportedly invested $1 billion to acquire a new technology aimed at targeting previously 'undruggable' cancer pathways, signaling a significant development for investors and cancer research.

An analysis evaluates whether Johnson & Johnson (JNJ) is a good stock investment opportunity for buyers.

Pharmaceutical giant Johnson & Johnson has committed $1 billion towards developing treatments for hard-to-treat cancers. This investment aims to advance research and bring new therapies to patients.

Predictions are being made regarding the future stock performance of major companies, with one forecast suggesting Google stock will reach $500 by a specific date. Another prediction speculates whether Johnson & Johnson stock will hit $300 this year.

Johnson & Johnson is set to acquire cancer drug technology developer Firefly Bio for $1 billion, while Incyte announced its acquisition of Vega Therapeutics for $1.25 billion. These deals highlight significant activity in the pharmaceutical and biotechnology sectors.

Financial analyst Jim Cramer noted that Johnson & Johnson faces no significant patent expirations, suggesting stability for the company.

Johnson & Johnson is reportedly strategizing to compete with AbbVie's most significant growth product. The article analyzes the potential market impact and investor considerations regarding this pharmaceutical industry development.

A study by Johnson & Johnson indicates that earlier administration of a prostate cancer drug leads to improved patient outcomes.

This article analyzes whether Johnson & Johnson's stock performance is currently surpassing that of the Dow Jones Industrial Average. It examines market data and trends to assess its relative strength.

Johnson & Johnson (JNJ) continues to be considered a defensive growth investment, suggesting stability and potential for expansion in its sector.

Johnson & Johnson (JNJ) has introduced a new, next-generation catheter designed for the treatment of coronary artery disease.

Johnson & Johnson has launched an interactive 'Gut Tunnel Experience' in Singapore to raise awareness about gut health.

Daniel Paksy, Managing Director of Johnson & Johnson Innovative Medicine for Greece and Romania, discusses how pharmaceutical innovation can serve as a tool for growth and resilience in the healthcare system.

The Russell 1000 Dividend ETF has reached a value of $125, with Johnson & Johnson highlighted for its performance in safety tests.

An article explores whether Johnson & Johnson continues to be considered the ultimate safe dividend stock for investors looking for stable returns.

Analysts on Wall Street are reportedly bullish on Johnson & Johnson stock, assessing its current market performance and future outlook.

Financial expert Jim Cramer has pointed out a significant trend affecting Johnson & Johnson (JNJ) shares.

Johnson & Johnson has announced positive results, highlighting sustained efficacy from its Vivacity-MG3 clinical trial.

Johnson & Johnson is utilizing artificial intelligence to significantly reduce the time required to identify promising chemical compounds and biologics for drug development, according to CIO Jim Swanson.

Johnson & Johnson (JNJ) has announced its first-quarter earnings, surpassing analyst expectations with strong financial results.

Johnson & Johnson (JNJ) is anticipated to break a six-session streak of losses in the stock market.

Johnson & Johnson's drug Imaavy has demonstrated long-term disease control in patients suffering from myasthenia gravis, offering a potential new treatment option.

This article provides a general overview of notable healthcare headlines for the week, highlighting companies like Johnson & Johnson, Abbott, and Organon.

Barclays has raised its price target for Johnson & Johnson, citing strong pharmaceutical momentum, while DA Davidson increased its price target for M&T Bank. These adjustments reflect positive outlooks from financial analysts.

Shares of Johnson & Johnson rose about 1% on Tuesday, with analysts discussing how the stock can build on its strong start.

Strong sales growth for Johnson & Johnson's Spravato, a nasal spray for treatment-resistant depression, is seen as a positive indicator for other companies developing psychedelic-based therapies.

Johnson & Johnson reported first-quarter profits that surpassed analyst estimates, even as sales of its key drug Stelara fell short of expectations.

An article provides a preview of what to expect from Johnson & Johnson's first-quarter earnings report. Analysts are anticipating key financial metrics and business segment performance.

An analysis highlights an $18 billion market reason to consider investing in a 147-year-old dividend-paying stock. The article suggests this long-standing company offers a compelling investment opportunity.

The US Food and Drug Administration has approved an expanded indication for J&J's Imaavy, allowing its use in treating wAIHA, broadening the therapeutic applications for the pharmaceutical product.

An analysis evaluates how well pharmaceutical giants Pfizer and Johnson & Johnson are prepared to navigate the challenges posed by upcoming patent expirations.

An analysis compares Abbott Labs and Johnson & Johnson, evaluating which 'Dividend King' stock presents a better buying opportunity for investors.

Johnson & Johnson has reportedly sent an important 11-word message to its shareholders, providing insight into the company's future direction.

Johnson & Johnson's dividend is evaluated as well-positioned for long-term stability, reflecting the company's robust financial health and commitment to shareholder returns.

Johnson & Johnson has maintained a record of increasing its dividend for 64 consecutive years, with an analysis provided on the annual payout for a $10,000 investment.

Financial commentator Jim Cramer has identified pharmaceutical giants like Johnson & Johnson (JNJ) and Eli Lilly (LLY) as strong investment opportunities. He highlights these companies as innovative plays outside the traditional technology sector.

An analysis suggests that Procter & Gamble (PG), Johnson & Johnson (JNJ), and Coca-Cola (KO) stocks could deliver unexpected positive results for investors in the coming year.

Johnson & Johnson has secured FDA approval for its new surgical robot, Ottava, after years of development and significant investment, aiming to challenge existing competitors in the operating room technology market.

An analysis compares the market positions of healthcare giants Johnson & Johnson and Danaher following their recent earnings reports, evaluating which stock is better positioned.

A former Johnson & Johnson employee, a retired industrial engineer, has been sentenced to a 22-month prison term for the possession of child sexual abuse images.

An explainer delves into whether Johnson & Johnson can finally resolve the extensive talc litigation it faces, which has been a significant legal and financial challenge for the company.

Johnson & Johnson has proposed a $5.5 billion settlement to resolve the remaining litigation related to its talc products.

Johnson & Johnson has reached a comprehensive settlement agreement covering approximately 76,000 ovarian cancer claims, potentially ending a decade of litigation, pending acceptance by 95% of claimants.

Intuitive Surgical shares have rebounded as analysts on Wall Street perceive underlying strength in the company, even in the face of competition from Johnson & Johnson.

Johnson & Johnson is reportedly becoming a more focused company, indicating a strategic shift towards a narrower business scope than previously maintained.

Johnson & Johnson's multiple myeloma drugs, Tecvayli and Talvey, have shown promising results in late-stage trials, significantly boosting cancer-free survival rates for patients.

Johnson & Johnson has secured a significant win with its new robotic surgical system, marking a key development in medical technology.

An article provides an in-depth analysis of the recent investor call regarding Johnson & Johnson (JNJ) stock, interpreting key takeaways for investors.

An analysis compares Johnson & Johnson and Eli Lilly and Company to determine which pharmaceutical giant's stock presents a better investment opportunity in 2026.

Johnson & Johnson announced an improved financial outlook for fiscal year 2026, following a strong performance in its second quarter.

Johnson & Johnson experienced a slowdown in growth momentum across its various segments and regions during the second quarter.

Analysts are forecasting a positive second-quarter earnings report for Johnson & Johnson, even as the company faces challenges related to its drug Stelara.

This article examines the strategies of Johnson & Johnson and AbbVie in their pursuit of pharmaceutical market dominance, identifying a potential winner between the two.

Following a recent run-up in Johnson & Johnson's stock, unusual put option activity has been observed, indicating potential investor sentiment shifts.

Johnson & Johnson is reportedly withdrawing from the lucrative $100 billion obesity market. This strategic decision raises questions about its long-term investment potential compared to competitors like Eli Lilly.

Johnson & Johnson (JNJ) has introduced its new dual-energy cardiac ablation catheter in Europe, expanding its medical device offerings in the region.

Johnson & Johnson has won a lawsuit in which three women alleged that the company's talc products caused their cancer, marking a legal victory for the pharmaceutical giant.

Pharmaceutical giants Lilly, Johnson & Johnson, and AbbVie have seen their stock prices hit new 52-week highs, indicating strong performance in the healthcare sector.

The CEO of Johnson & Johnson now foresees a clear path to achieving double-digit growth for the $100 billion company, signaling positive prospects for investors.

Several safe dividend stocks, including Johnson & Johnson, Altria, and Verizon, experienced an increase in their share prices today.

Johnson & Johnson is investing in U.S. manufacturing to bolster its vision business segment.

Reports indicate that 'smart money' investors are moving away from technology stocks and investing in Johnson & Johnson, anticipating a potential market downturn.

The CEO of Johnson & Johnson has stated that achieving cures for certain types of cancer within the next ten years is a realistic goal. This optimistic outlook highlights ongoing advancements in medical research and treatment.

An article explores potential factors that could drive Johnson & Johnson (JNJ) stock higher from its current position.

Jim Cramer has expressed his positive outlook on drug stocks, specifically mentioning Johnson & Johnson, and also highlighted the scarcity value of food stocks like J. M. Smucker.

Johnson & Johnson has triggered a $1 billion bet in the oncology sector, prompting analysis on whether its stock is a buy at $238.

Jim Cramer has been actively discussing various market trends, including elevated CPI as 'artificial inflation,' and offering specific stock recommendations. He has provided insights on companies like NVIDIA, Tractor Supply, and Home Depot, among others.

Johnson & Johnson continues to grow despite market challenges, maintaining its position as a defensive anchor with 60 years of rising dividends and market leadership in three-quarters of its core areas. The company is seeing record adoption of new medications, even with a significant sales decline for its blockbuster drug Stelara.

An investment analysis explores why Johnson & Johnson might be considered one of the most reliable dividend stocks for investors seeking stability.

Alvotech is once again seeking US regulatory approval for its biosimilar versions of Johnson & Johnson's Simponi and Regeneron's Eylea. This marks another attempt by the company to bring these treatments to the American market.

A Johnson & Johnson drug has shown effectiveness in reducing the risk of prostate cancer spread and death. The company is also seeking expanded use for the drug following a positive study on head and neck cancer.

A late-stage study has revealed that Johnson & Johnson's prostate cancer drug significantly reduces the risk of cancer spread and death. This finding marks a potential advancement in prostate cancer treatment.

DePuy, a subsidiary of Johnson & Johnson, has secured the rights to MinMaxMedical's Gemtrack technology.

Johnson & Johnson Innovative Medicine's General Manager for Vietnam, Upendra Patkie, stated that every US$1 invested in healthcare can generate up to US$4 in economic returns for Vietnam by creating a healthier workforce.

This article provides a forecast for Johnson & Johnson's stock price performance in the year 2027.

Several notable analysts have identified Dell, Johnson & Johnson, and AMD stocks among their top investment recommendations for the current week.

Leerink analysts upgraded Johnson & Johnson shares from hold to a buy equivalent, citing the company's promising slate of new drugs. This positive assessment comes in an AI-obsessed market, highlighting the value of traditional healthcare innovation.

CNBC reports on the most significant analyst calls made on Wall Street on Wednesday, covering companies such as Nvidia, Apple, Micron, Amazon, AMD, and Johnson & Johnson.

Johnson & Johnson has achieved a significant milestone for one of its most promising products currently in development.

Analysis suggests that Johnson & Johnson's accelerating growth trajectory provides justification for its current higher stock valuation multiple.

Johnson & Johnson has announced the discontinuation of several CAR-T cell therapy programs aimed at treating large B-cell lymphoma, impacting its oncology pipeline.

The Johnson & Johnson talcum powder case, which recently commenced in the High Court, has expanded to include 7,000 claimants. This development makes it the largest product liability case in the history of the United Kingdom.

Johnson & Johnson (JNJ) has been recognized by Reddit users as one of the top 10 best quality dividend stocks available for purchase.

Johnson & Johnson's medications Xarelto and Invokana are slated to become accessible through the TrumpRx platform.

An analysis suggests that Johnson & Johnson (JNJ) represents a growth engine available at a value price, indicating potential investment opportunities for shareholders.

Financial commentator Jim Cramer provided a range of opinions on various stocks, including calling a CrowdStrike sell-off a mistake and recommending Applied Materials as a "great buy." He also offered advice on Salesforce, AES Corporation, and other companies.

Guggenheim has increased its price target for Johnson & Johnson (JNJ) due to the potential upside from Icotyde, while maintaining a 'Buy' rating on the stock.

Following its Q1 2026 earnings report, an analysis evaluates whether Johnson & Johnson stock presents a buying opportunity for investors. The assessment considers the company's financial performance and future outlook.

Biotechnology company MeiraGTx is exploring a $100 million equity offering, coming after its recent gene therapy agreement with pharmaceutical giant Johnson & Johnson.

Johnson & Johnson updated its 2026 outlook, projecting $11.30-$11.50 EPS and a $100.2 billion sales midpoint, with an overall target of $100 billion in annual revenue.

Johnson & Johnson has announced that it is raising its dividend for the 64th consecutive year.

Johnson & Johnson reported quarterly revenue that surpassed analyst estimates and maintained its full-year financial outlook.

Johnson & Johnson is experiencing gains driven by the strong performance and growth of its innovative medicine division.